gene expression analysis
MindX Sciences Aims to Bring Objectivity to Psychiatric Disorder Testing With RNA Expression Markers
Premium
MindX has inked a deal that enables Q2 Solutions to use whole-transcriptome analysis for psychiatric blood tests as part of an early-access program for physicians.
The 20-year study showed the test provided an accurate assessment of the risk of long-term metastases and mortality for patients with localized prostate cancer.Â
DARPA program managers said they are developing different testing modalities that are crucially linked in their objective to facilitate more comprehensive and faster testing.
The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.
DermTech Enters Agreement With Blue Cross Blue Shield of Texas for Skin Cancer Assay
DermTech said its gene expression-based Pigmented Lesion Assay for the early detection of melanoma is now available as an in-network option for BCBSTX members.